Pancreatic ductal adenocarcinoma (PDAC) features a prominent stromal microenvironment
with remarkable cellular and spatial heterogeneity that meaningfully impacts disease …

Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types.
Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression …

Recent advances in targeted therapy and immunotherapy have once again raised the hope
that a cure might be within reach for many cancer types. Yet, most late-stage cancers are …

The discovery that the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) can
induce apoptosis of cancer cells without causing toxicity in mice has led to the in-depth study …

Pancreatic ductal adenocarcinoma carries a dismal prognosis, and outcomes have
improved little with modern therapeutics. Checkpoint-based immunotherapy has failed to …

Background Pancreatic ductal adenocarcinoma (PDAC) is most aggressive among all
gastrointestinal tumors. The complex intra-tumor heterogeneity and special tumor …

Pancreatic Adenocarcinoma | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …

Pancreatic cancer is characterized by inter-tumoral and intra-tumoral heterogeneity,
especially in genetic alteration and microenvironment. Conventional therapeutic strategies …

Regulatory T (Treg) cell infiltration constitutes a prominent feature of pancreatic ductal
adenocarcinoma (PDA). However, the immunomodulatory function of Treg cells in PDA is …

Pancreas ductal adenocarcinoma (PDAC) has one of the worst 5-year survival rates of all
solid tumors, and thus new treatment strategies are urgently needed. Here, we report that …